3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Endocrine
2
CNS
2
Genitourinary
1
Conditions
Carcinoma, Renal Cell
8
von Hippel-Lindau Disease
3
Pheochromocytoma
2
Paraganglioma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neoplasm Metastasis
1
Metastatic Castration-Resistant Prostate Cancer
1
Kidney Neoplasms
1
Hemangioblastoma
1
Endometrial Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma
1
Breast Neoplasms
1
Adenoma, Islet Cell
1
Interventions
gallium Ga 68 dotatate
4
lutetium Lu 177 dotatate
2
belzutifan
2
Fluorodeoxyglucose F18
2
3-fluorobenzylguanidine
2
olaparib
1
fluorodopa F 18
1
fludarabine phosphate
1
Specimen Handling
1
Phenoxybenzamine
1
Magnetic Resonance Spectroscopy
1
Interleukin-13
1
Genetic Testing
1
Cyclophosphamide
1
Blood Specimen Collection
1
Biopsy
1
6-fluorodopamine
1
3-Iodobenzylguanidine
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Pheochromocytoma
×
belzutifan
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled